Ausgabe 6/2019
Inhalt (22 Artikel)
Delineation of proapoptotic signaling of anthracene-shelled M2L4 metallacapsules and their synergistic activity with curcumin in cisplatin-sensitive and resistant tumor cell lines
Rositsa Mihaylova, Anife Ahmedova, Denitsa Momekova, Georgi Momekov, Nikolay Danchev
LEF1-AS1 contributes to proliferation and invasion through regulating miR-544a/ FOXP1 axis in lung cancer
Ansheng Wang, Chengling Zhao, Yuan Gao, Guixin Duan, Yuming Yang, Bo Fan, Xiaojing Wang, Kangwu Wang
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma
Sonia Brun, Firas Bassissi, Cindy Serdjebi, Marie Novello, Jennifer Tracz, François Autelitano, Marie Guillemot, Philippe Fabre, Jérôme Courcambeck, Christelle Ansaldi, Eric Raymond, Philipe Halfon
Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer
Juan Tang, Na Wang, JingBo Wu, PeiRong Ren, JunYang Li, LiShi Yang, XiangXiang Shi, Yue Chen, ShaoZhi Fu, Sheng Lin
A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damage
Hyun-Cheol Kang, Eui Kyu Chie, Hak Jae Kim, Jin Ho Kim, Il Han Kim, Kwangsoo Kim, Beom Su Shin, EunSook Ma
A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer
Xiaoli Liu, Wei Wang, Yanping Yin, Ming Li, Hong Li, Hang Xiang, Ao Xu, Xiaodong Mei, Bo Hong, Wenchu Lin
Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion
Fa-an Miao, Kun Chu, Hai-rong Chen, Meng Zhang, Pei-cong Shi, Jin Bai, Yong-ping You
Novel palladium (II) complexes with tetradentate thiosemicarbazones. Synthesis, characterization, in vitro cytotoxicity and xanthine oxidase inhibition
Dilşad Özerkan, Onur Ertik, Buşra Kaya, Serap Erdem Kuruca, Refiye Yanardag, Bahri Ülküseven
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials
Dylan J. Martini, Yuan Liu, Julie M. Shabto, Colleen Lewis, Meredith R. Kline, Hannah Collins, Mehmet Akce, Haydn T. Kissick, Bradley C. Carthon, Walid L. Shaib, Olatunji B. Alese, Rathi N. Pillai, Conor E. Steuer, Christina S. Wu, David H. Lawson, Ragini R. Kudchadkar, Viraj A. Master, Bassel F. El-Rayes, Suresh S. Ramalingam, Taofeek K. Owonikoko, R. Donald Harvey, Mehmet Asim Bilen
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
Makoto Nishio, Haruyasu Murakami, Yuichiro Ohe, Toyoaki Hida, Hiroshi Sakai, Kazuo Kasahara, Fumio Imamura, Tomohisa Baba, Kaoru Kubota, Yukio Hosomi, Tsuneo Shimokawa, Hidetoshi Hayashi, Kazutaka Miyadera, Tomohide Tamura
Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors
Fei Tang, Eleftheria Tsakalozou, Susanne M. Arnold, Chee M. Ng, Markos Leggas
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer
Haris Zahoor, Maria C. Mir, Pedro C. Barata, Andrew J. Stephenson, Steven C. Campbell, Amr Fergany, Robert Dreicer, Jorge A. Garcia
A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component
Inkeun Park, Hyo Jin Lee, Woo Kyoon Bae, Shinkyo Yoon, Jae Lyun Lee
A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia
Kara D. Capriotti, Milan Anadkat, Jennifer Choi, Benjamin Kaffenberger, Beth McLellan, Samuel Barone, Oluwaseun Kukoyi, Shari Goldfarb, Mario Lacouture
Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab
Hayato Kawachi, Daichi Fujimoto, Takeshi Morimoto, Kazutaka Hosoya, Yuki Sato, Mariko Kogo, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Keisuke Tomii
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, Yoshihiko Taniguchi, Toshihide Yokoyama, Yasushi Fukuda, Katsuya Hirano, Hirotaka Matsumoto, Ryota Kominami, Hidekazu Suzuki, Tomonori Hirashima, Junji Uchida, Mitsunori Morita, Masaki Kanazu, Nobuhiko Sawa, Yoshinori Kinoshita, Satoshi Hara, Toru Kumagai, Daichi Fujimoto
Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy?
Giandomenico Roviello, Navid Sohbani, Roberto Petrioli, Maria Grazia Rodriquenz
Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma
G. Beinse, A. Hulin, Benoit Rousseau
Cellular uptake evaluation of pentagamaboronon-0 (PGB-0) for boron neutron capture therapy (BNCT) against breast cancer cells
Adam Hermawan, Ratna Asmah Susidarti, Ratna Dwi Ramadani, Lailatul Qodria, Rohmad Yudi Utomo, Miki Ishimura, Yoshihide Hattori, Yoichiro Ohta, Mitsunori Kirihata, Edy Meiyanto
Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells
Jian-Ning Yao, Xue-Xiu Zhang, Yan-Zhen Zhang, Jia-Heng Li, Dong-Yao Zhao, Bing Gao, Hai-Ning Zhou, Shi-Lin Gao, Lian-Feng Zhang
Correction to: Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway
Piming Zhao, Ana E. Aguilar, Joanna Y. Lee, Lucy A. Paul, Jung H. Suh, Latika Puri, Meng Zhang, Jennifer Beckstead, Andrzej Witkowski, Robert O. Ryan, Julie D. Saba
Correction to: Inhibitory effects of tea polyphenols by targeting cyclooxygenase-2 through regulation of nuclear factor kappa B, Akt and p53 in rat mammary tumors
Preeti Roy, Jasmine George, Smita Srivastava, Shilpa Tyagi, Yogeshwer Shukla